What is AggreDyne?
AggreDyne is a prominent medical diagnostic company dedicated to pioneering advanced diagnostic tools that elevate patient care standards. The company's core innovation lies in its flagship product, the AggreGuide A-100, a sophisticated yet user-friendly system employing patented light scattering technology for precise platelet function assessment. This technology is designed for deployment across various healthcare settings, including hospital laboratories, specialized physician office laboratories, and large regional reference laboratories. Established in 2011 and based in Houston, Texas, AggreDyne's diagnostic solutions have received FDA clearance and CE marking, signifying their compliance with rigorous international regulatory standards.
How much funding has AggreDyne raised?
AggreDyne has raised a total of $102K across 1 funding round:
Debt
$102K
Debt (2021): $102K with participation from PPP
Key Investors in AggreDyne
PPP
Public-Private Partnership
What's next for AggreDyne?
With its substantial late-stage funding and strategic investment, AggreDyne is poised for accelerated growth and market penetration. The company's focus on enhancing patient care through advanced diagnostics, particularly in platelet function assessment, positions it favorably within the evolving healthcare landscape. Future strategic initiatives are likely to involve scaling manufacturing capabilities, expanding its sales and distribution networks, and potentially exploring new applications or enhancements for its patented technology. This capital infusion will be instrumental in solidifying AggreDyne's market position and driving innovation in diagnostic medicine.
See full AggreDyne company page
